Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes said today that it inked an exclusive agreement with JointPoint to co-market its surgery navigation software platform in the U.S.
The company’s technology features non-invasive navigation, pre-operative digital templating, case planning and feedback during total hip replacement surgeries.
“We are thrilled to partner with JointPoint to help provide more predictive outcomes for surgeons and their patients,” Aaron Villaruz, DePuy Synthes’ global hip platform leader, said in prepared remarks. “By providing access to important information at key stages of the hip replacement process, together we can help surgeons streamline cases and allow for pre-surgical goals to be achieved more consistently.”
JointPoint touts its OneTrial feature, which predicts optimal implant combinations based on pre-surgical goals using two images during the procedure. OneTrial can also give precise recommendations for the size and position of DePuy Synthes’ implants, the company said.
“During hip replacement surgery, physicians strive for optimal implant choices and positioning to improve patient satisfaction by achieving proper leg length, offset, and cup positioning. JointPoint Hip Navigation System gives surgeons the confidence with real time feedback so they can ultimately help restore patients back to their natural function efficiently while minimizing fluoroscopy,” Dr. Andrew Cooper added.”I’m excited about what JointPoint can offer those surgeons whose patients are good candidates for the anterior approach.”
The companies plan to start co-marketing the software in the second half of this year.
See the best minds in medtech live at DeviceTalks Boston on Oct. 2.
The post DePuy, JointPoint ink joint surgery navigation deal appeared first on MassDevice.
from MassDevice http://ift.tt/2xzx6Md
Cap comentari:
Publica un comentari a l'entrada